1. Israel Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
OWC Pharmaceutical Research Corp.

OWC Pharmaceutical Research Corp.

OWCP
OWC Pharmaceutical Research Corp.US flagOther OTC
0.00
USD
- -
- -
4,975.00Market Cap
OWC Pharmaceutical Research Corp.
OWCP
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2011
2012
2013
2014
2015
2016
2017
2018
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.55
-0.02
-0.01
-0.02
-0.1
-0.02
-0.02
-0.03
-0.07
0.01
Basic EPS, GAAP
-0.67
-0.01
- -
- -
-0.01
-0.02
-0.01
-0.01
-0.02
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.53
- -
- -
- -
-0.11
-0.09
-0.1
-0.1
-0.18
-0.12
Book Value per Share
0.82
-0.01
-0.01
-0.01
0.03
- -
- -
0.01
-0.06
-0.02
Tangible Book Value per Share
- -
5
16
19
52
81
96
145
148
196
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
-4,196.15
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
-5
-2
-2
-5
-10
1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
-4,574.66
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
1
- -
- -
1
3
1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
1
- -
- -
1
-9
-4
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-6.02
Return on Capital (%)
- -
- -
-53,645.51
-169,765.33
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'19
Jun'19
Sep'19
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
176
216
244
Market Capitalization
5
3
2

Working Capital

FRC

•

in mil. unless spec.
Mar'19
Jun'19
Sep'19
Total Current Assets
3
2
2
Cash, Cash Equivalents & STI
3
2
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-404.04%
-1,293.43%
Free Cash Flow
- -
172.67%
111.29%
Net Income, GAAP
- -
337.64%
125.01%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2017
-0.01
- -
-0.01
- -
-0.03
2018
-0.01
-0.02
-0.01
- -
-0.07
2019
-0.01
0.04
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -
Similar Companies
Cipher Pharmaceuticals Inc. (CPHRF)
Lannett Company, Inc. (LCI)
Granules India Limited (GRANULES.BO)
Acorda Therapeutics, Inc. (ACORQ)
Almirall, S.A. (ALM.MC)
Panacea Life Sciences Holdings, Inc. (PLSH)
Business
OWC Pharmaceutical Research Corp. (OWCP) engages in the research and development of cannabis-based medical products through its wholly-owned Israeli subsidiary, One World Cannabis Ltd.; these products target conditions including multiple myeloma, psoriasis, post-traumatic stress disorder, chronic pain, and fibromyalgia, with a focus on a proprietary cannabis soluble tablet delivery system and topical creams; the company also provides consulting services to firms and governmental agencies on international medical cannabis protocols and regulations. Founded in 2008 and headquartered in Ramat Gan, Israel, OWC Pharmaceutical Research operates primarily in the pharmaceuticals and biotechnology sector, with emphasis on cannabinoid therapies for global medical markets. Previously known as Dynamic Applications Corp., the company changed its name in December 2014; it signed an agreement with a US partner for advance funding against future royalties, initially targeting commercialization of its psoriasis cream, and entered an equity purchase agreement with Kodiak Capital Group for up to $750,000 to support development efforts.